Charlie's Holdings Details Executive Equity Awards Through 2024
Ticker: CHUC · Form: DEF 14A · Filed: Jun 24, 2025 · CIK: 1134765
| Field | Detail |
|---|---|
| Company | Charlie'S Holdings, Inc. (CHUC) |
| Form Type | DEF 14A |
| Filed Date | Jun 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, Equity Awards, DEF 14A, Corporate Governance, Shareholder Dilution, Medicinal Chemicals, Biotech
Related Tickers: CHUC
TL;DR
**CHUC's heavy reliance on equity awards for executives signals a long-term play, but watch for potential dilution.**
AI Summary
Charlie's Holdings, Inc. (CHUC) filed a DEF 14A on June 24, 2025, outlining executive compensation and equity award details for the fiscal years ending December 31, 2022, 2023, and 2024. The filing indicates a focus on equity-based incentives for both named executive officers (PEO) and non-PEO NEOs. For 2024, the fair value of equity awards granted and vested for PEOs was recorded, alongside changes in fair value of prior year equity awards. The company, operating in Medicinal Chemicals & Botanical Products, continues to utilize equity compensation as a key component of its strategic outlook, aligning executive interests with long-term shareholder value. Specific dollar amounts for revenue and net income are not detailed in this particular DEF 14A, which primarily focuses on compensation disclosures. Risks related to compensation structures and their impact on executive retention are implicitly present, though not explicitly quantified as financial risks in this filing. The strategic outlook suggests a continued reliance on performance-based equity to drive future growth and operational efficiency.
Why It Matters
This DEF 14A filing provides crucial transparency into Charlie's Holdings' executive compensation practices, particularly its reliance on equity awards. For investors, understanding these structures helps assess management's alignment with shareholder interests and potential dilution from future vesting. Employees, especially executives, are directly impacted by these incentives, which can influence retention and performance. In the competitive Medicinal Chemicals & Botanical Products sector, attractive compensation packages are vital for securing top talent, making these disclosures a benchmark against peers. The broader market gains insight into CHUC's governance and its approach to long-term value creation through executive incentives.
Risk Assessment
Risk Level: medium — The filing indicates a significant use of equity awards for executive compensation across 2022, 2023, and 2024. While aligning interests, this strategy carries dilution risk for existing shareholders if not managed effectively. The lack of specific dollar values for total compensation or performance metrics in this snippet makes a full risk assessment challenging, but the focus on equity suggests potential volatility in executive pay tied to stock performance.
Analyst Insight
Investors should scrutinize Charlie's Holdings' upcoming financial statements for the full impact of these equity awards on share count and earnings per share. Evaluate the performance metrics tied to these awards to ensure they are rigorous and aligned with long-term shareholder value creation.
Financial Highlights
- debt To Equity
- 0.0
- revenue
- $0
- operating Margin
- 0%
- total Assets
- $0
- total Debt
- $0
- net Income
- $0
- eps
- $0
- gross Margin
- 0%
- cash Position
- $0
- revenue Growth
- +0%
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Not Disclosed | Principal Executive Officer | $0 |
| Not Disclosed | Principal Financial Officer | $0 |
| Not Disclosed | Other Named Executive Officers (PEO) | $0 |
| Not Disclosed | Non-PEO NEOs | $0 |
Key Numbers
- 2025-06-24 — Filing Date (Date the DEF 14A was filed by Charlie's Holdings, Inc.)
- 2025-08-07 — Conformed Period of Report (The period to which the DEF 14A report conforms.)
- 2024-12-31 — Fiscal Year End (The end of the latest fiscal year covered by equity award data.)
- 001-32420 — SEC File Number (Unique identifier for Charlie's Holdings, Inc. with the SEC.)
Key Players & Entities
- Charlie's Holdings, Inc. (company) — Filer of DEF 14A
- SEC (regulator) — Recipient of DEF 14A filing
- 03 Life Sciences (company) — Organization Name associated with filer
- True Drinks Holdings, Inc. (company) — Former company name of Charlie's Holdings, Inc.
- BAZI INTERNATIONAL, INC. (company) — Former company name of Charlie's Holdings, Inc.
- XELR8 HOLDINGS, INC. (company) — Former company name of Charlie's Holdings, Inc.
- PEO (person) — Named Executive Officers
- Non-PEO NEO (person) — Non-Named Executive Officers
FAQ
What is the primary purpose of Charlie's Holdings' DEF 14A filing?
The primary purpose of Charlie's Holdings' DEF 14A filing on June 24, 2025, is to disclose information related to executive compensation, specifically detailing equity awards for named executive officers and non-PEO NEOs for the fiscal years ending December 31, 2022, 2023, and 2024.
How does Charlie's Holdings compensate its executives according to this filing?
According to the DEF 14A, Charlie's Holdings compensates its executives significantly through equity awards. The filing provides data on the fair value of equity awards granted and vested, as well as changes in fair value of prior year awards for both PEOs and Non-PEO NEOs across 2022, 2023, and 2024.
What fiscal years are covered by the equity award data in Charlie's Holdings' DEF 14A?
The equity award data in Charlie's Holdings' DEF 14A covers the fiscal years ending December 31, 2022, December 31, 2023, and December 31, 2024, providing a three-year overview of executive compensation practices.
What is the potential impact of Charlie's Holdings' equity compensation on investors?
For investors, Charlie's Holdings' reliance on equity compensation could lead to potential share dilution if a large number of shares are issued upon vesting. It also aligns executive interests with stock performance, which can be a positive, but requires careful monitoring of the company's share count and earnings per share.
What industry does Charlie's Holdings, Inc. operate in?
Charlie's Holdings, Inc. operates in the Medicinal Chemicals & Botanical Products industry, as indicated by its Standard Industrial Classification (SIC) code 2833.
When was Charlie's Holdings, Inc. formerly known as True Drinks Holdings, Inc.?
Charlie's Holdings, Inc. was formerly known as True Drinks Holdings, Inc. before a name change that occurred on January 22, 2013.
What is the business address for Charlie's Holdings, Inc.?
The business address for Charlie's Holdings, Inc. is 1007 Brioso Dr., Costa Mesa, CA 92627, with a business phone number of 949-570-0691.
Does the DEF 14A filing for Charlie's Holdings include revenue and net income figures?
No, this specific DEF 14A filing for Charlie's Holdings primarily focuses on executive compensation and equity award disclosures. It does not explicitly detail revenue or net income figures for the company.
What is the significance of the 'Conformed Period of Report' date for Charlie's Holdings?
The 'Conformed Period of Report' date of August 7, 2025, for Charlie's Holdings indicates the period to which the information in the DEF 14A filing conforms, often relating to the upcoming annual meeting or proxy solicitation period.
How can investors assess the effectiveness of Charlie's Holdings' executive compensation plan?
Investors can assess the effectiveness of Charlie's Holdings' executive compensation plan by examining the performance metrics tied to the equity awards, comparing executive pay to company performance (e.g., stock price, profitability), and benchmarking against industry peers to ensure competitive yet responsible compensation practices.
Industry Context
Charlie's Holdings, Inc. operates within the Medicinal Chemicals & Botanical Products sector. This industry is characterized by a focus on natural ingredients and their application in health and wellness products. Companies in this space often navigate complex regulatory environments and rely on innovation to differentiate their offerings. The competitive landscape includes both established players and emerging brands, with a growing consumer interest in plant-based solutions.
Regulatory Implications
As a company in the medicinal chemicals and botanical products sector, Charlie's Holdings, Inc. is subject to regulations from bodies like the FDA concerning product safety, efficacy, and labeling. Changes in these regulations or increased scrutiny can impact product development, marketing, and market access. Compliance with these evolving standards is critical for maintaining operational integrity and consumer trust.
What Investors Should Do
- Review executive compensation structure for alignment with performance.
- Monitor industry trends and regulatory changes.
- Analyze historical equity award valuations.
Key Dates
- 2025-06-24: DEF 14A Filing — Indicates the company has disclosed executive compensation and equity award details for the relevant fiscal periods.
- 2025-08-07: Conformed Period of Report — Defines the reporting period for which the information in the DEF 14A is considered.
- 2024-12-31: Fiscal Year End — Marks the end of the most recent fiscal year for which equity award data is presented.
- 2013-01-22: Name Change from True Drinks Holdings, Inc. — Historical information showing a previous corporate identity.
- 2010-08-03: Name Change from BAZI INTERNATIONAL, INC. — Historical information showing an earlier corporate identity.
- 2007-03-21: Name Change from XELR8 HOLDINGS, INC. — Historical information showing a very early corporate identity.
Glossary
- DEF 14A
- A proxy statement filing with the SEC that provides detailed information about corporate governance, executive compensation, and matters to be voted on by shareholders. (This filing type is the primary source for the disclosed executive compensation and equity award information.)
- PEO
- Principal Executive Officer, typically the Chief Executive Officer (CEO) of the company. (Identifies the top executive for whom compensation and equity awards are disclosed.)
- Non-PEO NEO
- Non-Principal Executive Officer Named Executive Officer. These are other key executives of the company, such as the CFO, COO, or other senior vice presidents. (Includes other highly compensated executives whose compensation is detailed in the filing.)
- Fair Value of Equity Awards
- The estimated worth of stock options, restricted stock units, or other equity-based compensation at the time of grant or vesting, often calculated using models like Black-Scholes. (This is a key metric used to quantify the value of executive compensation in this filing.)
- Vesting Date
- The date on which an executive earns the right to receive or exercise an equity award, typically subject to continued employment or performance conditions. (Crucial for understanding when equity awards become the property of the executive.)
- Fiscal Year End
- The last day of a company's accounting period, which is December 31st for Charlie's Holdings, Inc. (Establishes the timeframe for the financial and compensation data presented.)
- SEC File Number
- A unique identifier assigned by the Securities and Exchange Commission to each company's filings. (Helps in locating and referencing specific company filings.)
- Medicinal Chemicals & Botanical Products
- An industry classification for companies involved in the production of chemicals derived from plants for medicinal purposes. (Defines the sector in which Charlie's Holdings, Inc. operates.)
Year-Over-Year Comparison
This DEF 14A filing, dated June 24, 2025, primarily focuses on executive compensation and equity award details for fiscal years ending up to December 31, 2024. Specific comparative financial metrics such as revenue growth, margin changes, or updated risk factors from a previous filing are not detailed within this document itself. The emphasis is on the structure and valuation of executive incentives, particularly equity-based awards, and their changes over the covered fiscal periods.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 24, 2025 by PEO regarding Charlie's Holdings, Inc. (CHUC).